VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Comparison

ADS-MVA vaccine Double Inactivated whole SARS-CoV vaccine Double Inactivated whole SARS-CoV vaccine + alum β-propiolactone-inactivated SARS-CoV vaccine MA-ExoN vaccine MVA/S vaccine RBD-rAAV-SARS-CoV RBD-rAAV-SARS-CoV-version-02 rDNA-expressed S protein + alum vaccine rDNA-expressed S protein vaccine Recombinant spike polypeptide vaccine rMA15-ΔE vaccine rMV-S + rMV-N vaccine rMV-SARS-CoV-S/Ssol SARS Subunit Spike Protein with subunit boosting Vaccine SARS-CoV Ad S/N vaccine SARS-CoV CRT-N vaccine SARS-CoV CTLA4-S DNA vaccine SARS-CoV M protein DNA vaccine SARS-CoV N + SARS-CoV M DNA vaccine SARS-CoV N protein DNA vaccine SARS-CoV pCI-N DNA from vaccine SARS-CoV rVV-SARS-N SARS-CoV Salmonella-CTLA4-S DNA vaccine SARS-CoV Salmonella-tPA-S DNA vaccine SARS-CoV tPA-S DNA vaccine SARS-CoV VLP-MHV + alum vaccine SARS-CoV VLP-MHV vaccine UV Inactivated SARS-CoV vaccine UV-Inactivated SARS-CoV + TLR Agonist Vaccine VRP-MERS-N vaccine VRP-SARS-N vaccine
Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: S protein(Chen et al., 2005)
  • S protein gene of SARS-CoV gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Vector: live-attenuated modified vaccinia virus Ankara (MVA) (Chen et al., 2005)
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: Recombinant live-attenuated modified vaccinia virus Ankara (MVA) had full-length SARS-CoV envelope Spike (S) glycoprotein gene was introduced into the deletion III region of the MVA genome.
    (Chen et al., 2005)
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: whole virus (Tseng et al., 2012)
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: Inactivated whole virus by formalin and Ultraviolet radiation, hence Double Inactivated (DI) Vaccine (Tseng et al., 2012)
  • Type: Inactivated or "killed" vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: whole virus(Tseng et al., 2012)
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: Inactivated whole virus by formalin and Ultraviolet radiation with alum vaccine (Tseng et al., 2012)
  • Type: Inactivated or "killed" vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: whole virus (See et al., 2006)
  • Immunization Route: subcutaneous injection
  • Description: whole killed (inactivated by beta-propiolactone) SARS-CoV vaccine (See et al., 2006)
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: MA-ExoN (Graham et al., 2012)
  • Immunization Route: intranasal immunization
  • Description: Live-attenuated RNA virus vaccine with engineered inactivation of SARS-CoV ExoN activity (MA-ExoN) (Graham et al., 2012)
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: S protein (Bisht et al., 2004)
  • S protein gene of SARS-CoV gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Vector: highly attenuated modified vaccinia virus Ankara (Bisht et al., 2004)
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: Recombinant form of the highly attenuated modified vaccinia virus Ankara (MVA) containing the gene encoding full-length SARS-CoV S (Bisht et al., 2004)
  • Vaccine Ontology ID: VO_0004678
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Preparation: Inactivated SARS coronavirus (SARS-CoV) vaccine with adjuvant (Zheng et al., 2008).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004679
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Preparation: RBD-rAAV prime/RBD-specific T cell peptide boost (Du et al., 2008).
  • Immunization Route: Intramuscular injection (i.m.)
  • Type: DNA vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: ectodomain of the S protein(Tseng et al., 2012)
  • Immunization Route: intranasal immunization
  • Description: rDNA-expressed ectodomain of the S protein + alum vaccine (Tseng et al., 2012)
  • Type: DNA vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: ecto-domain of S protein (Tseng et al., 2012)
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: rDNA-expressed ectodomain of the S protein vaccine
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: S protein (Woo et al., 2005)
  • S protein gene of SARS-CoV gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Description: intraperitoneal recombinant spike polypeptide generated by amplify gene encoding amino acids residues 14-667 of S protein that was cloned BamHI and KpnI sites of vector pQE-31 that was generated by Escherichia coli (Woo et al., 2005)
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: virulent mouse-adapted SARS-CoV with E-deletion (rMA15-ΔE) (Fett et al., 2013)
  • envelope protein (E) gene of SARS-CoV gene engineering:
    • Type: Gene mutation
    • Detailed Gene Information: Click Here.
  • Immunization Route: intranasal immunization
  • Description: recombinant MA15 virulent mouse-adapted SARS-CoV (MA15) background of E-deleted vaccine candidate (rMA15-ΔE) (Fett et al., 2013)
  • Type: Mixed vaccine of two viral vector vaccines
  • Status: Research
  • Host Species for Licensed Use: Mouse
  • Antigen: codon-optimised spike glycoprotein (S), SARS-CoV nucleocapsid protein (N) (Liniger et al., 2008)
  • Vector: Live-attenuated recombinant measles virus (rMV) (Liniger et al., 2008).
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Description: Live attenuated recombinant measles viruses (rMV) expressing a codon-optimised spike glycoprotein (S) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) (Weingartl et al., 2004).
  • Vaccine Ontology ID: VO_0004711
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • S protein gene of SARS-CoV gene engineering:
    • Type: Recombinant vector construction
    • Description: A live attenuated recombinant meas(Escriou et al., 2014)s vaccine (MV) candidates expressing either the membrane-anchore SARS-CoV spike (S) protein (Escriou et al., 2014).
    • Detailed Gene Information: Click Here.
  • Preparation: Live attenuated recombinant measles vaccine (MV) candidates expressing either the membrane-anchored SARS-CoV spike (S) protein or its secreted soluble ectodomain (Ssol) (Escriou et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0011486
  • Type: Recombinant vector vaccine
  • Status: Research
  • S protein gene of SARS-CoV gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Vector: Adeno-associated virus (Du et al., 2008).
  • Immunization Route: Subcutaneous injection
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: S protein, N (See et al., 2006)
  • S protein gene of SARS-CoV gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • nucleocapsid protein (N) gene of SARS-CoV gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Vector: attenuated adenovirus(See et al., 2006)
  • Immunization Route: intranasal immunization
  • Description: A combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein (See et al., 2006)
  • Type: DNA vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: N protein (Kim et al., 2004)
  • Immunization Route: Intravenous injection (i.v.)
  • Description: A DNA vaccine encoding CRT linked to a SARS-CoV N (Kim et al., 2004)
  • Type: DNA vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: S protein(Woo et al., 2005)
  • S protein gene of SARS-CoV gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: CTLA4HingeSARS800 DNA from SARS-CoV S protein vaccine (Woo et al., 2005)
  • Type: DNA vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: membrane protein (M) (Shi et al., 2006)
  • membrane protein (M) gene of SARS-CoV gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: DNA vaccine made from recombinant plasmid containing membrane protein (M) sequence constructed then expressed and purified from E. coli bacteria (Shi et al., 2006)
  • Type: DNA vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: N, membrane protein (M) (Shi et al., 2006)
  • nucleocapsid protein (N) gene of SARS-CoV gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • membrane protein (M) gene of SARS-CoV gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: DNA vaccine made from recombinant plasmids containing membrane protein (M) and nucleocapsid protein (N) sequences constructed then expressed and purified from E. coli bacteria (Shi et al., 2006)
  • Type: Subunit vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: N (Shi et al., 2006)
  • nucleocapsid protein (N) gene of SARS-CoV gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: DNA vaccine made from recombinant plasmid containing nucleocapsid protein (N) sequence constructed then expressed and purified from E. coli bacteria (Shi et al., 2006)
  • Type: DNA vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: S protein (Zhao et al., 2005)
  • nucleocapsid protein (N) gene of SARS-CoV gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: A plasmid pCI-N, encoding the full-length N gene of SARS-CoV, was constructed and expressed in Escherichia coli DH5alpha (Zhao et al., 2005)
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: N protein (Zhao et al., 2016)
  • Vector: recombinant vaccinia virus (Zhou et al., 2006)
  • Immunization Route: intranasal immunization
  • Description: recombinant vaccinia virus expressing the N protein (rVV-SARS-N)
  • Type: DNA vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: S protein (Woo et al., 2005)
  • S protein gene of SARS-CoV gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Immunization Route: Oral
  • Description: oral live-attenuated auxotrophic S. typhimurium aroA strain SL7207 that contained CTLA4HingeSARS800 DNA vaccine (Woo et al., 2005)
  • Type: DNA vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: S protein (Woo et al., 2005)
  • S protein gene of SARS-CoV gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Immunization Route: Oral
  • Description: oral live-attenuated auxotrophic S. typhimurium aroA strain SL7207 that contained tPA-optimize800 DNA vaccine (Woo et al., 2005)
  • Type: DNA vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: S protein (Woo et al., 2005)
  • S protein gene of SARS-CoV gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: tPA-optimize800 DNA vaccine of SARS-CoV S protein (Woo et al., 2005)
  • Type: Virus like particle vaccine
  • Status: Licensed
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: SARS-CoV spike protein (S) (Tseng et al., 2012)
  • Vector: Nucleocapsid (N), envelope (E) and membrane (M) proteins from mouse hepatitis coronavirus (MHV) (Tseng et al., 2012)
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: Virus like particle vaccine produced from SARS-CoV spike protein (S) and the Nucleocapsid (N), envelope (E) and membrane (M) proteins from mouse hepatitis coronavirus (MHV) (Tseng et al., 2012)
  • Type: Virus like particle vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: SARS-CoV spike protein (S) (Tseng et al., 2012)
  • Vector: Nucleocapsid (N), envelope (E) and membrane (M) proteins from mouse hepatitis coronavirus (MHV) (Tseng et al., 2012)
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: Virus like particle vaccine produced from SARS-CoV spike protein (S) and the Nucleocapsid (N), envelope (E) and membrane (M) proteins from mouse hepatitis coronavirus (MHV) (Tseng et al., 2012)
  • Type: Live, attenuated vaccine
  • Status: Licensed
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: whole virus(Iwata-Yoshikawa et al., 2014)
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: Ultraviolet radiation applied to SARS virus. Vaccine causes eosinophilic immunopathology to SARS while providing protection (Iwata-Yoshikawa et al., 2014)
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: whole virus (Iwata-Yoshikawa et al., 2014)
  • Immunization Route: subcutaneous injection
  • Description: Ultraviolet radiation is used to inactivate SARS-CoV and a Toll-Like Receptor Agonist Adjuvant is added to prevent eosinophilic immunopathology (Iwata-Yoshikawa et al., 2014).
  • Type: Viral Like Particle Vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: N protein (Zhao et al., 2016)
  • Vector: Venezuelan equine encephalitis replicons (Zhao et al., 2016)
  • Immunization Route: intranasal immunization
  • Description: Venezuelan equine encephalitis replicons bearing epitopes of N protein from MERS(Zhao et al., 2016). Identical to VRP-MERS-N vaccine (Vaccine 5748).
  • Type: Viral Like Particle Vaccine
  • Status: Licensed
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: CD4+ T cell epitope in the nucleocapsid (N) protein of SARS-CoV (N353) (Zhao et al., 2016)
  • Vector: Venezuelan equine encephalitis replicons (VRP) (Zhao et al., 2016)
  • Immunization Route: intranasal immunization
  • Description: Venezuelan equine encephalitis replicons (VRP) encoding a SARS-CoV CD4+ T cell epitope vaccinated intranasally. Does not have same efficacy if vaccinated subcutaneously (Zhao et al., 2016)
    Identical to VRP-SARS-N vaccine (Vaccine 5755).
Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response

Mouse Response

  • Host Strain: Balb/c (Chen et al., 2005)
  • Vaccination Protocol: immunized intramuscular injection twice with a 3-week interval. Two mice were given 2 × 106 TCID50 of the vaccine, and six mice received 2 × 10^7 TCID50.(Chen et al., 2005)
  • Immune Response: testing hosts generated high levels of neutralizing antibodies (Chen et al., 2005)

Mouse Response

  • Host Strain: Balb/c and C57BL/6 (Tseng et al., 2012)
  • Vaccination Protocol: Each mouse received 100 µl injection of each vaccine intramuscularly on days 0 and 28. The injection was done at 1 µg, 0.5 µg, 0.25 µg, 0.125 µg of the vaccine (Tseng et al., 2012)
  • Immune Response: Increased titer of neutralizing antibodies and reduced viral titer (Tseng et al., 2012)
  • Side Effects: Eosinophil infiltration in the lung lesions after challenge, type-2 hypersensitivity reaction (Tseng et al., 2012)
  • Challenge Protocol: On day 56 after first vaccination, each mice was challenged challenged with 106TCID50/60 µl of SARS-CoV intranasally (IN) and euthanized on day 58 (Tseng et al., 2012)
  • Efficacy: protected (Tseng et al., 2012)

Mouse Response

  • Host Strain: BALB/c (Tseng et al., 2012)
  • Vaccination Protocol: Each mouse received 100 µl injection of each vaccine intramuscularly on days 0 and 28. The injection was done at 1 µg, 0.5 µg, 0.25 µg, 0.125 µg of the vaccine (Tseng et al., 2012)
  • Immune Response: Increased titer of neutralizing antibodies and reduced viral titer that are higher than without adjuvant, neutrophil + eosinophil infiltration, Th2-type hypersensitivity reaction. (Tseng et al., 2012)
  • Side Effects: eosinophil infiltration in the lung lesions after challenge, lower than without adjuvant (Tseng et al., 2012)
  • Challenge Protocol: On day 56 after first vaccination, each mice was challenged challenged with 106TCID50/60 µl of SARS-CoV intranasally (IN) and euthanized on day 58 (Tseng et al., 2012)
  • Efficacy: protected (Tseng et al., 2012)

Mouse Response

  • Host Strain: 129S6/SvEv
  • Vaccination Protocol: Vaccination at 0 weeks and 4 weeks (See et al., 2006)
  • Immune Response: A 19-fold difference (P=0·02) in total SARS-CoV-specific IgG levels and lung viral titers were reduced by 4 logs to undetectable levels compared with titers observed in the PBS control on day 3 post-challenge, vaccinated animals showed significantly higher levels (P=0·002) of IFN-γ than control animals (See et al., 2006).
  • Challenge Protocol: Vaccination at 0 weeks and 4 weeks challenged by SARS-CoV-Tor2 at week 7 (See et al., 2006)

Mouse Response

  • Host Strain: Balb/c(Graham et al., 2012)
  • Vaccination Protocol: intranasally with varying doses (10^2–10^4 PFU, depending on the experiment) of SARS-CoV MA-ExoN (Graham et al., 2012)
  • Immune Response: generated high levels of neutralizing antibodies (Graham et al., 2012)
  • Challenge Protocol: intranasally injected 1e2.5 vaccination PFU of vaccine of SARS-CoV MA-ExoN then given SARS-CoV once recovered (Graham et al., 2012)
  • Efficacy: complete protection (Graham et al., 2012)

Mouse Response

  • Host Strain: Balb/c(Bisht et al., 2004)
  • Vaccination Protocol: Mice were inoculated i.n. or i.m. with 10^7 pfu of MVA/S at time 0 and again at 4 weeks. (Bisht et al., 2004)
  • Immune Response: Antibodies neturalized SARS-CoV in vitro after 2 doses (Bisht et al., 2004)
  • Challenge Protocol: inoculated intranasally or intramuscularly with 7log pfu of MVA at 0 and 4 weeks then challenged with TCID50 of SARS-CoV (Bisht et al., 2004)
  • Efficacy: little to no replication of SARS-CoV in the respiratory tracts after internasal inoculation(Bisht et al., 2004)

Mouse Response

  • Vaccination Protocol: Intranasal vaccination with RBD-rAAV (Zheng et al., 2008).
  • Vaccine Immune Response Type: VO_0000287
  • Immune Response: Induced production of IgG and IgA that exhibited neutralizing activity. Induced a markedly higher level of antigen specific IL-2+ T cells but a slightly lower level of IFN-γ+ T cells in the spleen, IFN-γ-producing CD3+/CD8+ T cells were significantly higher in the splenocytes of RBD-rAAV intranasally versus intramuscularly vaccinated mice. (Zheng et al., 2008)
  • Challenge Protocol: Mice were challenged with 10^5 TCID50f SARS-CoV strain GZ50 (Zheng et al., 2008).
  • Efficacy: RBD-rAAV vaccination provoked a prolonged antibody response with continually increasing levels of neutralising activity. When compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide boost induced similar levels of Th1 and neutralising antibody responses that protected vaccinated mice from subsequent SARS-CoV challenges,but stronger Th2 and CTL responses (Zheng et al., 2008).

Mouse Response

  • Host Strain: Balb/c (Du et al., 2008)
  • Vaccination Protocol: Mice were separated into 4 groups (9 mice per group) and primed with RBD-rAAV [intramuscular (i.m.), 2 × 10^11 VP /200 μl)] or RBD-peptides (N50 and N60, 50 μg each) plus CpG ODN (25 μg) [subcutaneous, (s.c.)] or blank AAV, and boosted with RBD-rAAV or RBD-Pep or AAV, respectively (Du et al., 2008).
  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: Induced high level of IgG Ab response, reaching a peak 3 months post-vaccination, plateaued for 3 months, then decreased. Mucosal IgA Ab peaked 1 month after vaccination, then decreased in the next 5 months. Vaccination induced high levels of Agspecific IL-2+ T cells but slightly lower levels of IFN-γ+ T cells in the spleen. Single dose did not trigger significant IL-2+ and IFN-γ+ T cell response. (Du et al., 2008)
  • Challenge Protocol: Forty days post-vaccination, mice were anaesthetized with isoflurane and i.n. inoculated with 50 μl of SARS-CoV strain GZ50 (5 × 10^5 TCID50) (Du et al., 2008).
  • Efficacy: Compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide (RBD-Pep) boost induced similar levels of Th1 and neutralizing antibody responses that protected the vaccinated mice from subsequent SARS-CoV challenge, but stronger Th2 and CTL responses. No significant immune responses and protective effects were detected in mice vaccinated with RBD-Pep or blank AAV alone (Du et al., 2008).

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Each mouse received 100 µl injection of the vaccine intramuscularly on days 0 and 28. This was done at 2 µg, 1 µg, 0.5 µg, 0.5 µg of the vaccine per injection (Tseng et al., 2012)
  • Immune Response: Increased titer of neutralizing antibodies and reduced viral titer, higher titer of neutralizing antibodies without adjuvant (Tseng et al., 2012)
  • Side Effects: eosinophil infiltration in the lung lesions after challenge, lessened compared to without adjuvant (Tseng et al., 2012)
  • Challenge Protocol: On day 56 after first vaccination, each mice was challenged challenged with 10^6TCID50/60 µl of SARS-CoV intranasally (IN) and euthanized on day 58 (Tseng et al., 2012)
  • Efficacy: protected(Tseng et al., 2012)

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Each mouse received 100 µl injection of the vaccine intramuscularly on days 0 and 28. This was done at 2 µg, 1 µg, 0.5 µg, 0.5 µg of the vaccine per injection (Tseng et al., 2012)
  • Immune Response: Increased titer of neutralizing antibodies and reduced viral titer (Tseng et al., 2012)
  • Side Effects: eosinophil infiltration in the lung lesions after challenge (Tseng et al., 2012)
  • Challenge Protocol: On day 56 after first vaccination, each mice was challenged challenged with 106TCID50/60 µl of SARS-CoV intranasally (IN) and euthanized on day 58 (Tseng et al., 2012)
  • Efficacy: protected (Tseng et al., 2012)

Mouse Response

  • Host Strain: Balb/c (H-2d)
  • Vaccination Protocol: 50 μg administered via intraperitoneal route on days 0, 14, and 28. (Woo et al., 2005)
  • Immune Response: No neutralizing antibody production, high IgG levels, lymphocyte proliferation, production of IFN-γ >6000 pg/ml at 48hrs and 72hrs, detectable production of IL-4 at 24hrs (Woo et al., 2005)

Mouse Response

  • Host Strain: Balb/c
  • Immune Response: Induced neutralizing antibodies, Produced optimal levels of CD4 and CD8 T cells (Fett et al., 2013)
  • Side Effects: Minor peribronchial and perivascular infiltration in aged (18-month-old) mice (Fett et al., 2013)
  • Challenge Protocol: Mice were challenged with 10^5 PFU of MA15 at day 21 after immunization. (Fett et al., 2013)
  • Efficacy: Protected (Fett et al., 2013)

Mouse Response

  • Host Strain: Ifnartm-CD46Ge transgenic mice(Liniger et al., 2008)
  • Vaccination Protocol: Mice were immunized with 0.5 × 10^4 pfu of each recombinant virus per mouse (Liniger et al., 2008)
  • Immune Response: Induction of both humoral neutralizing and cellular responses against SARS-CoV, and neutralizing immunity against MV. (Liniger et al., 2008)

Mouse Response

  • Host Strain: CD46-IFNAR (Escriou et al., 2014)
  • Vaccination Protocol: Mice were immunized with two intraperitoneal (i.p.) injections at 4-week interval of 10^5 TCID50 of MV-S or MV-Ssol recombinant viruses (Escriou et al., 2014).
  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: Production of anti-SARS IgG (specifically IgG2a) after 1 dose, increased by 10-20 fold after second dose. Induced production of neutralizing antibodies, as well as moderate levels of anti-SARS IgA antibodies (Escriou et al., 2014)
  • Challenge Protocol: Mice were inoculated intranasally with 105 pfu of SARS-CoV five weeks after the second immunization (Escriou et al., 2014).
  • Efficacy: Recombinant MV expressing the anchored full-length S induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV (Escriou et al., 2014).

Mouse Response

  • Host Strain: BALB/c (Du et al., 2008)
  • Vaccination Protocol: Mice were Mice were separated into 4 groups (9 mice per group) and primed with RBD-rAAV [intramuscular (i.m.), 2 × 10^11 VP /200 μl)] or RBD-peptides (N50 and N60, 50 μg each) plus CpG ODN (25 μg) [subcutaneous, (s.c.)] or blank AAV, and boosted with RBD-rAAV or RBD-Pep or AAV, respectively (Du et al., 2008).
  • Immune Response: Vaccination increased production (P < 0.05) of IL-4-producting Th2 cells higher than those in RBD-rAAV prime/RBD-rAAV vaccinated animals, but a lower level (P < 0.05) of IL-10-secreting Th2 cells that play roles in down-regulation of immune responses, as compared to those of RBD-rAAV prime/RBD-rAAV boost vaccination. RBD-rAAV prime/RBD-pep exhibited similar frequencies of IFN-γ-producing cells (Th1) to RBD-rAAV prime/RBD-rAAV boost vaccinated animals. Increased production of IL-2-secreting cells. Induction of SARS-CoV-specific IgG production. (Du et al., 2008)
  • Challenge Protocol: Mice intranasally challenged with SARS-CoV strain GZ50 40 days post-vaccination (Du et al., 2008).
  • Efficacy: SARS-CoV viral load in lung tissues was significantly reduced in mice vaccinated with RBD-Pep. Very low level of viral load was detected in lung tissues of RBD-rAAV prime/RBD-Pep boost group, similar to that in lung tissues of RBD-rAAV prime/RBD-rAAV boost group. Vaccination of RBD-rAAV prime/RBD-peptide boost was able to significantly inhibit SARS-CoV infection (Du et al., 2008).

Mouse Response

  • Host Strain: 129S6/SvEv (See et al., 2006)
  • Vaccination Protocol: Mouse was immunized on day 0 and week 4 (See et al., 2006)
  • Immune Response: Quantifiable humoral response with presence of SARS-CoV-specific IgG1 and a significant reduction in level of SARS-CoV RNA in lung titers. Production of IFN-γ. (See et al., 2006)
  • Challenge Protocol: Mouse was immunized on day 0 and week 4 and then challenged with SARS-COV Tor2 at week 7 (See et al., 2006).
  • Efficacy: Partially protected (See et al., 2006)

Mouse Response

  • Host Strain: C57BL/6 (Kim et al., 2004)
  • Vaccination Protocol: DNA-coated gold particles were prepared and delivered to the shaved abdominal regions of mice using a helium-driven gene gun (Bio-Rad) with a discharge pressure of 400 lb/in2. C57BL/6 mice were immunized with 2 μg of the plasmid encoding CRT/N protein. The mice received two boosters with the same dose at a 1-week interval. (Kim et al., 2004)
  • Immune Response: Significantly increased neutralizing antibody titre to N protein DNA vaccine (Vaccine 5732) and significantly greater count of INF-gamma CD8_ lymphocytes within splenocytes (Kim et al., 2004)
  • Challenge Protocol: Vaccinated mice challenged with DNA encoding CRT/Na nd challenged these mice with Vac-N or Vac-WT (Recombinant vaccinnia virus expressing SARS N protein or wild-type vaccinia virus, respectively) intranasally or intravenously 1 week after the last vaccination (Kim et al., 2004)
  • Efficacy: significantly reduced viral titer load(Kim et al., 2004)

Mouse Response

  • Host Strain: Balb/c (H-2d) (Woo et al., 2005)
  • Vaccination Protocol: 100 μg intramuscular administration of vaccine, then 50 μg intraperitoneal injection at 14 and 28 days (Woo et al., 2005)
  • Immune Response: Induced neutralizing antibody, high IgG levels, lymphocyte proliferation, production of IFN-γ, production of IL-4 (48hrs)
    (Woo et al., 2005)

Mouse Response

Mouse Response

  • Host Strain: Balb/c (Shi et al., 2006)
  • Vaccination Protocol: 20 μg of intramuscular vaccine injection (Shi et al., 2006)
  • Immune Response: Production of N-specific IgG antibodies (paricularly IgG2a), Lymphocyte proliferation, Production of IFN-γ, IL-2, IL-4, Increased CD4+ and CD8+ levels (Shi et al., 2006)

Mouse Response

  • Vaccination Protocol: DNA-coated gold particles were prepared and delivered to the shaved abdominal regions of mice using a helium-driven gene gun (Bio-Rad) with a discharge pressure of 400 lb/in2. C57BL/6 mice were immunized with 2 μg of the plasmid encoding N protein. The mice received two boosters with the same dose at a 1-week interval. (Kim et al., 2004)
  • Immune Response: Significantly increased neutralizing antibody titer to N protein DNA vaccine and significantl count of INF-gamma CD8_ lymphocytes within splenocytes (Kim et al., 2004)
  • Challenge Protocol: Challenge Protocol: Vaccinated mice challenged with DNA encoding N and challenged these mice with Vac-N or Vac-WT (Recombinant vaccinnia virus expressing SARS N protein or wild-type vaccinia virus, respectively) intranasally or intravenously 1 week after the last vaccination (Kim et al., 2004)
  • Efficacy: reduced viral titer load(Kim et al., 2004)

Mouse Response

  • Host Strain: Balb/c (Shi et al., 2006)
  • Vaccination Protocol: 20 μg of vaccine intramuscular injection (Shi et al., 2006)
  • Immune Response: Production of N-specific IgG antibodies (paricularly IgG2a), Lymphocyte proliferation, Production of IFN-γ, IL-2, IL-4, Increased CD4+ and CD8+ levels
    (Shi et al., 2006)

Mouse Response

  • Host Strain: Balb/c(Zhao et al., 2005)
  • Vaccination Protocol: 200 μg of Vaccine 573 in both tibialis anterior muscles three times at 2-week intervals (Zhao et al., 2005)
  • Immune Response: Anti-N immunoglobulins (specifically IgG2a) and splenocytes proliferative responses against N protein, splenocyte production of IFN-γ, IL-2, IL-4, IL-10, production of N-specific CD8+ T cells, delayed-type hypersensitivity response
    (Zhao et al., 2005)
  • Side Effects: Delayed hypersensitivity response (Zhao et al., 2005)

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Mice were vaccinated with rVV-SARS-N i.n. and boosted 6–7 weeks later.
  • Immune Response: Production of N-specific CD4+ T cells, Production of IFN-γ, Production of IL-10, Increased mobilization of CD8+ cells to infected lung. (Zhao et al., 2016)
  • Efficacy: protected (Zhao et al., 2016)

Mouse Response

  • Host Strain: Balb/ (H-2d) (Woo et al., 2005)
  • Vaccination Protocol: : oral injection of 6e9 live attenuated Salmonella typhimurium that underwent transfection of CTLA4-, then 50 μg spike polypeptide administered via intraperitoneal injection on days 28 and 42. (Woo et al., 2005)
  • Immune Response: Immune Response Description: neutralizing antibody titers of <1:20–1:160, lymphocyte proliteration, production of IFN-γ, production of IL-4 (48hrs) (Woo et al., 2005)

Mouse Response

  • Host Strain: Balb/c (H-2d) (Woo et al., 2005)
  • Vaccination Protocol: oral injection of 6e9 live attenuated Salmonella typhimurium that underwent transfection of tPA-S (Woo et al., 2005)
  • Immune Response: neutralizing antibody titers of <1:20–1:160, lymphocyte proliteration, production of IFN-γ, production of IL-4 (48hrs) (Woo et al., 2005)

Mouse Response

  • Host Strain: Balb/c (H-2d) (Woo et al., 2005)
  • Vaccination Protocol: 100 μg of intramuscular administration of vaccine then 50 μg intraperitoneal injection of spike polypeptide at 28 and 42 days (Woo et al., 2005)
  • Immune Response: neutralizing antibody titers of <1:20–1:160, lymphocyte proliteration, production of IFN-γ, production of IL-4 (48hrs) (Woo et al., 2005)

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Each mouse received 100 µl injection containing 2 µg of vaccine intramuscularly on days 0 and 28 (Tseng et al., 2012)
  • Immune Response: Increased titer of neutralizing antibodies and reduced viral titer (Tseng et al., 2012)
  • Side Effects: eosinophil infiltration in the lung lesions after challenge (Tseng et al., 2012)
  • Challenge Protocol: On day 56 after first vaccination, each mice was challenged challenged with 10^6TCID50/60 µl of SARS-CoV intranasally (IN) and euthanized on day 58 (Tseng et al., 2012)
  • Efficacy: protected (Tseng et al., 2012)

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Each mouse received 100 µl injection containing 2 µg of vaccine intramuscularly on days 0 and 28 (Tseng et al., 2012)
  • Immune Response: Induced neutralizing antibody, Neutrophil + eosinophil infiltration, Th2-type hypersensitivity reaction. (Tseng et al., 2012)
  • Side Effects: eosinophil infiltration in the lung lesions after challenge (Tseng et al., 2012)
  • Challenge Protocol: On day 56 after first vaccination, each mice was challenged challenged with 106TCID50/60 µl of SARS-CoV intranasally (IN) and euthanized on day 58 (Tseng et al., 2012)
  • Efficacy: protected (Tseng et al., 2012)

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: 10 μg UV-V subcutaneously injected in back and reimmunized 6 to 7 weeks later (Iwata-Yoshikawa et al., 2014)
  • Immune Response: Induced neutralizing antibodies, Lymphocyte infiltration, Upregulation of IL-4 and CCL24, CD11b+ cells upregulated genes associated with eosinophil induction (Iwata-Yoshikawa et al., 2014).
  • Side Effects: Eosinophil infiltration present in the lungs (Iwata-Yoshikawa et al., 2014)
  • Challenge Protocol: 10 week old BALB/c mice were vaccinated with 10 μg UV-V and boosted 6 weeks later. Four weeks afterwards, the animals were inoculated in the left nostril with 106.5 TCID50 in 30 μl of F-musX(Iwata-Yoshikawa et al., 2014).
  • Efficacy: Most mice survived challenge after weight loss and respiratory disease (Iwata-Yoshikawa et al., 2014)

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: 10 μg of UV-Inactivated SARS-CoV + TLR Agonist Vaccine subcutaneously injected in back and reimmunized 6 to 7 weeks later (Iwata-Yoshikawa et al., 2014)
  • Immune Response: Induced neutralizing antibodies (More than in UV-V), Lymphocyte infiltration, High levels of CXCL10 and CXCL1, Production of IFN-β, Upregulation of TNF-α1 (Iwata-Yoshikawa et al., 2014)
  • Side Effects: Minor eosinophil lung infiltration (Iwata-Yoshikawa et al., 2014)
  • Challenge Protocol: 10 week old BALB/c mice were vaccinated with 10 μg UV-V and boosted 6 weeks later. Four weeks afterwards, the animals were inoculated in the left nostril with 106.5 TCID50 in 30 μl of F-musX(Iwata-Yoshikawa et al., 2014)
  • Efficacy: All mice survived challenge (Iwata-Yoshikawa et al., 2014).

Mouse Response

  • Host Strain: Balb/c (H-2d)
  • Immune Response: Reduced viral titre, production of N-specific CD4+ T cells, Production of IFN-γ, Production of CD8+ T cells. (Zhao et al., 2016)
  • Challenge Protocol: Mice were challenged 4-6 weeks after boosting (Zhao et al., 2016)

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: vaccinated BALB/c mice twice at 6–7 week intervals with VRP-SARS-N at 100 PFU (Zhao et al., 2016)
  • Immune Response: Decreased viral titre, increase in N-specific CD4+ T cells and IFN-γ in lungs, production of IL-10, increased mobilization of CD8+ cells to infected lung. (Zhao et al., 2016)
  • Challenge Protocol: challenged 6-7 weeks after second vaccination with doses from 100, 500, 1,000 PFU of SARS-CoV (Zhao et al., 2005)
  • Efficacy: nearly complete protection at 100 pfu, protected at 500 and 1000 pfu doses (Zhao et al., 2016)
  • Description: Better results compared to different vaccination routes (Zhao et al., 2016).

Rabbit Response

  • Vaccination Protocol: immunized intramuscular injection twice with a 3-week interval (Chen et al., 2005)
  • Immune Response: testing hosts generated high levels of neutralizing antibodies (Chen et al., 2005)

Ferret Response

  • Vaccination Protocol: Each ferret was immunized with rMVA-S (ferrets 7 to 9), n day 0 with a dose of 1e8 PFU of the corresponding virus per ferret by intraperitoneal and subcutaneous routes, and a booster immunization was given on day 14 with the same regimen.(Weingartl et al., 2004)
  • Immune Response: Neutralizing activity was detected in sera along with a corresponding immunoglobin G titer collected from all three ferrets 7 days after booster immunization with rMVA-S virus, while the titer declined to undetectable level 14 days after the booster (Weingartl et al., 2004).
  • Side Effects: Ferrets immunized with rMVA-S (particularly ferret 9) developed severe periportal and panlobular mononuclear hepatitis in contrast to only mild periportal mononuclear hepatitis was observed in control ferrets (Weingartl et al., 2004) .
  • Challenge Protocol: Ferrets were challenged with 1e6 PFU of the SARS-CoV Tor2 isolate by the intranasal route(Weingartl et al., 2004).
  • Description: Study shows correlation with liver damage but does not definitely proof it is caused as SARS-CoV in ferrets also damage liver.(Weingartl et al., 2004)

Vole Response

Vole Response

  • Vaccination Protocol: 100 μg injected (Shi et al., 2006)
  • Immune Response: increased N-specific antibodies compared to Vaccine 5732, increased lymphocyte proliferation specific to N antigen than Vaccine 5732 (Shi et al., 2006)
  • Challenge Protocol: 100 μg injected (Shi et al., 2006)
  • Efficacy: 6/7 voles protected (Shi et al., 2006)

Vole Response

  • Host Strain: Microtus brandti raddes (Shi et al., 2006)
  • Vaccination Protocol: 100 μg injected (Shi et al., 2006)
  • Immune Response: increased N-specific antibodies, increased lymphocye proliferation specific to N antigen (Shi et al., 2006)
  • Challenge Protocol: 100 μg injected three times at an interval of 7 days and then challenged with live SARS-CoV (PUMC01) (Shi et al., 2006)

Macaque Response

  • Vaccination Protocol: immunized intramuscular injection twice with a 4-week interval. 1 × 10^8 TCID50 for the first immunization and a dose of 3 × 10^8 TCID50 for the second injection. (Chen et al., 2005)
  • Immune Response: testing hosts generated high levels of neutralizing antibodies after 2 vaccinations
    (Chen et al., 2005)
  • Challenge Protocol: immunized on days 0 and 28 via intranasal injection before challenged after second immunization on day 28 with 10^5 TCID50 of pathogenic SATS-CoVPUMC01.
    (Chen et al., 2005)
  • Efficacy: likely protected (Chen et al., 2005)
  • Description: After virus challenge, SARS-CoV shedding detected by RT-PCR was only detected in the nasopharyngeal specimens of one of the four ADS-MVA immunized animals (Rh0413) on day 2 after virus challenge. No virus shedding was detectable on days 4 and 6 postchallenge in these four macaques. SARS-CoV could not be isolated from the lung specimens of ADS-MVA-immunized macaques on day 7 postchallenge. (Chen et al., 2005)
References References References References References References References References References References References References References References References References References References References References References References References References References References References References References References References References
Chen et al., 2005: Chen Z, Zhang L, Qin C, Ba L, Yi CE, Zhang F, Wei Q, He T, Yu W, Yu J, Gao H, Tu X, Gettie A, Farzan M, Yuen KY, Ho DD. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. Journal of virology. 2005; 79(5); 2678-2688. [PubMed: 15708987].
Weingartl et al., 2004: Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, Smith G, Jones S, Proulx R, Deschambault Y, Grudeski E, Andonov A, He R, Li Y, Copps J, Grolla A, Dick D, Berry J, Ganske S, Manning L, Cao J. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. Journal of virology. 2004; 78(22); 12672-12676. [PubMed: 15507655].
Tseng et al., 2012: Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PloS one. 2012; 7(4); e35421. [PubMed: 22536382].
Tseng et al., 2012: Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PloS one. 2012; 7(4); e35421. [PubMed: 22536382].
See et al., 2006: See RH, Zakhartchouk AN, Petric M, Lawrence DJ, Mok CP, Hogan RJ, Rowe T, Zitzow LA, Karunakaran KP, Hitt MM, Graham FL, Prevec L, Mahony JB, Sharon C, Auperin TC, Rini JM, Tingle AJ, Scheifele DW, Skowronski DM, Patrick DM, Voss TG, Babiuk LA, Gauldie J, Roper RL, Brunham RC, Finlay BB. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. The Journal of general virology. 2006; 87(Pt 3); 641-650. [PubMed: 16476986].
Graham et al., 2012: Graham RL, Becker MM, Eckerle LD, Bolles M, Denison MR, Baric RS. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nature medicine. 2012; 18(12); 1820-1826. [PubMed: 23142821].
Bisht et al., 2004: Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, Moss B. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(17); 6641-6646. [PubMed: 15096611].
Zheng et al., 2008: Zheng BJ, Du LY, Zhao GY, Lin YP, Sui HY, Chan C, Ma S, Guan Y, Yuen KY. Studies of SARS virus vaccines. Hong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine. 2008; 14 Suppl 4; 39-43. [PubMed: 18708674].
Du et al., 2008: Du L, Zhao G, Lin Y, Chan C, He Y, Jiang S, Wu C, Jin DY, Yuen KY, Zhou Y, Zheng BJ. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine. 2008; 26(13); 1644-1651. [PubMed: 18289745].
Du et al., 2008: Du L, Zhao G, Lin Y, Sui H, Chan C, Ma S, He Y, Jiang S, Wu C, Yuen KY, Jin DY, Zhou Y, Zheng BJ. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. Journal of immunology (Baltimore, Md. : 1950). 2008; 180(2); 948-956. [PubMed: 18178835].
Tseng et al., 2012: Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PloS one. 2012; 7(4); e35421. [PubMed: 22536382].
Tseng et al., 2012: Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PloS one. 2012; 7(4); e35421. [PubMed: 22536382].
Woo et al., 2005: Woo PC, Lau SK, Tsoi HW, Chen ZW, Wong BH, Zhang L, Chan JK, Wong LP, He W, Ma C, Chan KH, Ho DD, Yuen KY. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine. 2005; 23(42); 4959-4968. [PubMed: 15993989].
Fett et al., 2013: Fett C, DeDiego ML, Regla-Nava JA, Enjuanes L, Perlman S. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein. Journal of virology. 2013; 87(12); 6551-6559. [PubMed: 23576515].
Liniger et al., 2008: Liniger M, Zuniga A, Tamin A, Azzouz-Morin TN, Knuchel M, Marty RR, Wiegand M, Weibel S, Kelvin D, Rota PA, Naim HY. Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine. 2008; 26(17); 2164-2174. [PubMed: 18346823].
Weingartl et al., 2004: Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, Smith G, Jones S, Proulx R, Deschambault Y, Grudeski E, Andonov A, He R, Li Y, Copps J, Grolla A, Dick D, Berry J, Ganske S, Manning L, Cao J. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. Journal of virology. 2004; 78(22); 12672-12676. [PubMed: 15507655].
Escriou et al., 2014: Escriou N, Callendret B, Lorin V, Combredet C, Marianneau P, FĂ©vrier M, Tangy F. Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. Virology. 2014; 452-453; 32-41. [PubMed: 24606680].
Du et al., 2008: Du L, Zhao G, Lin Y, Chan C, He Y, Jiang S, Wu C, Jin DY, Yuen KY, Zhou Y, Zheng BJ. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine. 2008; 26(13); 1644-1651. [PubMed: 18289745].
See et al., 2006: See RH, Zakhartchouk AN, Petric M, Lawrence DJ, Mok CP, Hogan RJ, Rowe T, Zitzow LA, Karunakaran KP, Hitt MM, Graham FL, Prevec L, Mahony JB, Sharon C, Auperin TC, Rini JM, Tingle AJ, Scheifele DW, Skowronski DM, Patrick DM, Voss TG, Babiuk LA, Gauldie J, Roper RL, Brunham RC, Finlay BB. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. The Journal of general virology. 2006; 87(Pt 3); 641-650. [PubMed: 16476986].
Kim et al., 2004: Kim TW, Lee JH, Hung CF, Peng S, Roden R, Wang MC, Viscidi R, Tsai YC, He L, Chen PJ, Boyd DA, Wu TC. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. Journal of virology. 2004; 78(9); 4638-4645. [PubMed: 15078946].
Woo et al., 2005: Woo PC, Lau SK, Tsoi HW, Chen ZW, Wong BH, Zhang L, Chan JK, Wong LP, He W, Ma C, Chan KH, Ho DD, Yuen KY. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine. 2005; 23(42); 4959-4968. [PubMed: 15993989].
Shi et al., 2006: Shi SQ, Peng JP, Li YC, Qin C, Liang GD, Xu L, Yang Y, Wang JL, Sun QH. The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization. Molecular immunology. 2006; 43(11); 1791-1798. [PubMed: 16423399].
Shi et al., 2006: Shi SQ, Peng JP, Li YC, Qin C, Liang GD, Xu L, Yang Y, Wang JL, Sun QH. The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization. Molecular immunology. 2006; 43(11); 1791-1798. [PubMed: 16423399].
Shi et al., 2006: Shi SQ, Peng JP, Li YC, Qin C, Liang GD, Xu L, Yang Y, Wang JL, Sun QH. The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization. Molecular immunology. 2006; 43(11); 1791-1798. [PubMed: 16423399].
Zhao et al., 2005: Zhao P, Cao J, Zhao LJ, Qin ZL, Ke JS, Pan W, Ren H, Yu JG, Qi ZT. Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine. Virology. 2005; 331(1); 128-135. [PubMed: 15582659].
Zhao et al., 2016: Zhao J, Zhao J, Mangalam AK, Channappanavar R, Fett C, Meyerholz DK, Agnihothram S, Baric RS, David CS, Perlman S. Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity. 2016; 44(6); 1379-1391. [PubMed: 27287409].
Zhou et al., 2006: Zhou Z, Post P, Chubet R, Holtz K, McPherson C, Petric M, Cox M. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine. 2006; 24(17); 3624-3631. [PubMed: 16497416].
Woo et al., 2005: Woo PC, Lau SK, Tsoi HW, Chen ZW, Wong BH, Zhang L, Chan JK, Wong LP, He W, Ma C, Chan KH, Ho DD, Yuen KY. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine. 2005; 23(42); 4959-4968. [PubMed: 15993989].
Woo et al., 2005: Woo PC, Lau SK, Tsoi HW, Chen ZW, Wong BH, Zhang L, Chan JK, Wong LP, He W, Ma C, Chan KH, Ho DD, Yuen KY. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine. 2005; 23(42); 4959-4968. [PubMed: 15993989].
Woo et al., 2005: Woo PC, Lau SK, Tsoi HW, Chen ZW, Wong BH, Zhang L, Chan JK, Wong LP, He W, Ma C, Chan KH, Ho DD, Yuen KY. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine. 2005; 23(42); 4959-4968. [PubMed: 15993989].
Tseng et al., 2012: Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PloS one. 2012; 7(4); e35421. [PubMed: 22536382].
Tseng et al., 2012: Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PloS one. 2012; 7(4); e35421. [PubMed: 22536382].
Iwata-Yoshikawa et al., 2014: Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, Tashiro M, Sata T, Hasegawa H, Nagata N. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. Journal of virology. 2014; 88(15); 8597-8614. [PubMed: 24850731].
Iwata-Yoshikawa et al., 2014: Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, Tashiro M, Sata T, Hasegawa H, Nagata N. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. Journal of virology. 2014; 88(15); 8597-8614. [PubMed: 24850731].
Zhao et al., 2016: Zhao J, Zhao J, Mangalam AK, Channappanavar R, Fett C, Meyerholz DK, Agnihothram S, Baric RS, David CS, Perlman S. Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity. 2016; 44(6); 1379-1391. [PubMed: 27287409].
Zhao et al., 2005: Zhao P, Cao J, Zhao LJ, Qin ZL, Ke JS, Pan W, Ren H, Yu JG, Qi ZT. Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine. Virology. 2005; 331(1); 128-135. [PubMed: 15582659].
Zhao et al., 2016: Zhao J, Zhao J, Mangalam AK, Channappanavar R, Fett C, Meyerholz DK, Agnihothram S, Baric RS, David CS, Perlman S. Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity. 2016; 44(6); 1379-1391. [PubMed: 27287409].
Zhao et al., 2016: Zhao J, Zhao J, Mangalam AK, Channappanavar R, Fett C, Meyerholz DK, Agnihothram S, Baric RS, David CS, Perlman S. Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity. 2016; 44(6); 1379-1391. [PubMed: 27287409].